《巴塞罗那肝癌临床分期预后评估与治疗推荐策略：2026更新版》摘译

薛继华; 叶庆芬; 陆荫英

doi:10.12449/JCH260814

《巴塞罗那肝癌临床分期预后评估与治疗推荐策略：2026更新版》摘译

DOI: 10.12449/JCH260814

1.
安徽医科大学第一附属医院感染病科，合肥 230022
2.
成都市公共卫生临床医疗中心，成都 610000
3.
中国人民解放军总医院第五医学中心肝病医学部，北京 100039

基金项目:

四大慢病重大专项 (2024ZD0526200)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：薛继华、叶庆芬负责翻译；陆荫英负责审校。薛继华与叶庆芬对本文贡献等同，同为第一作者。

详细信息

通信作者:
陆荫英， luyinying1973@163.com （ORCID： 0000-0002-7737-2334）

计量
- 文章访问数: 5
- HTML全文浏览量: 1
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2026-05-30
- 录用日期: 2026-06-08
- 出版日期: 2026-08-25

An excerpt of BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update

Jihua Xue¹,
Qingfen Ye²,
Yinying Lu^{3
, ,
,}

1.
Department of Infectious Diseases，The First Affiliated Hospital of Anhui Medical University，Hefei 230022，China
2.
Public Health Clinical Center of Chengdu，Chengdu 610000，China
3.
Senior Department of Hepatology，The Fifth Medical Center of PLA General Hospital，Beijing 100039，China

Research funding:

Noncommunicable Chronic Diseases-National Science and Technology Major Project (2024ZD0526200)

More Information

Corresponding author: Lu Yinying， luyinying1973@163.com （ORCID： 0000-0002-7737-2334）

摘要

摘要: 巴塞罗那肝癌临床分期（BCLC分期）系统是肝细胞癌预后评估与治疗决策的重要国际框架。BCLC 2026版在保留2022版总体架构的基础上，整合了局部治疗、系统治疗及肝移植领域的最新研究证据，强调各分期与循证医学支持的首次治疗选择直接对应，突出肝功能精细评估、个体化决策及复杂情境下的路径优化。本文对BCLC 2026版的核心观念、关键定义及各阶段首次治疗选择要点进行摘译，并结合我国临床实践作简要评述。
- 癌，肝细胞 /
- 巴塞罗那肝癌临床分期 /
- 预后 /
- 病人遴选 /
- 临床决策
Abstract: The Barcelona Clinic Liver Cancer （BCLC） system is a major international framework for hepatocellular carcinoma prognostic assessment and treatment decision-making. While preserving the overall architecture of the 2022 edition， the 2026 update integrates the latest research evidence in locoregional therapy， systemic therapy， and liver transplantation， emphasizes a direct correspondence between staging and evidence-based first-line treatment options， and highlights the refined assessment of liver function， individualized decision-making， and pathway optimization in complex scenarios. This article gives an excerpt of the core concepts， key definitions， and key points regarding first-line treatment options for different stages in the 2026 update， with brief comments on the clinical practice in China.
- Carcinoma， Hepatocellular /
- Barcelona Clinic Liver Cancer Staging /
- Prognosis /
- Patient Selection /
- Clinical Decision-Making

HTML全文

参考文献(2)

[1]

Reig M, Sanduzzi-Zamparelli M, Forner A, et al. BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update[J]. J Hepatol, 2026, 84( 3): 631- 654. DOI: 10.1016/j.jhep.2025.10.020.

[2]

National Clinical Research Center for Infectious Diseases; Society of Hepatology, Beijing Medical Association; Translational Medicine Branch, China Association of Gerontology and Geriatrics. Expert consensus on precise diagnosis and management of primary hepatocellular carcinoma in advanced stage(2023 version)[J]. Chin J Hepatol, 2023, 31( 9): 910- 920. DOI: 10.3760/cma.j.cn501113-20230717-00006.

国家感染性疾病临床医学研究中心, 北京医学会肝病学分会, 中国老年学及老年医学学会转化医学分会. 晚期原发性肝癌精细化诊疗管理专家共识(2023年版)[J]. 中华肝脏病杂志, 2023, 31( 9): 910- 920. DOI: 10.3760/cma.j.cn501113-20230717-00006.

施引文献

资源附件(0)

访问统计